Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TNO155 |
Synonyms | |
Therapy Description |
TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent tumor cell growth (PMID: 38032104, Cancer Res (2022) 82 (12_Supplement): 1054). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TNO155 | TNO-155|TNO 155 | SHP2 Inhibitor 20 | TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent tumor cell growth (PMID: 38032104, Cancer Res (2022) 82 (12_Supplement): 1054). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK R1275Q | neuroblastoma | sensitive | TNO155 | Preclinical - Cell culture | Actionable | In a preclinical study, TNO155 decreased viability of neuroblastoma cell lines harboring ALK R1275Q in culture (PMID: 38032104). | 38032104 |
ROS1 D2113N | Advanced Solid Tumor | sensitive | TNO155 | Preclinical - Cell culture | Actionable | In a preclinical study, TNO155 inhibited proliferation of transformed cells expressing ROS1 D2113N in culture (PMID: 37587872). | 37587872 |
ALK F1174L | neuroblastoma | sensitive | TNO155 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TNO155 decreased viability and invasion of neuroblastoma cell lines harboring ALK F1174L in culture and decreased tumor growth and cell invasion and increased survival in cell line xenograft models (PMID: 38032104). | 38032104 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | TNO155 | Preclinical - Cell culture | Actionable | In a preclinical study, TNO155 inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03114319 | Phase I | TNO155 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | NLD | ITA | ESP | CAN | 4 |